Free Shipping on Orders Over $149 — Lab-Tested 99%+ Purity — USA Shipped

CJC-1295 (with DAC) 5mg - Research Peptide
Body Composition 5mg

CJC-1295 (with DAC)

$95.00 In Stock

Extended half-life GHRH analogue with Drug Affinity Complex for sustained GH research.

≥98%
HPLC Purity
COA
Included
USA
Based Supplier

Description

Extended half-life GHRH analogue with Drug Affinity Complex for sustained GH research.

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue conjugated with a maleimidopropionic acid (MPA) linker that binds covalently to serum albumin after injection. This albumin conjugation dramatically extends the peptide's half-life from approximately 30 minutes to 6-8 days, enabling sustained elevation of growth hormone levels from a single administration. The mechanism involves the same GHRH receptor activation as the non-DAC version, but the prolonged pharmacokinetic profile produces continuous rather than pulsatile GH stimulation. In a pivotal pharmacokinetic study, Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) demonstrated that a single 60 mcg/kg subcutaneous dose of CJC-1295 with DAC produced sustained GH elevation for 6-14 days and elevated IGF-1 levels for 9-11 days in healthy adult subjects, with a 1.5 to 2-fold increase in mean GH concentrations. This sustained profile is both an advantage and a consideration: while it reduces dosing frequency, the continuous GH elevation does not replicate the natural pulsatile pattern of endogenous GH secretion. Compared to CJC-1295 without DAC, the DAC version is suited for research protocols requiring prolonged GH axis stimulation, while the non-DAC form better models physiological pulse dynamics. Research also suggests potential applications in lean mass preservation, bone mineral density, and sleep quality improvement through sustained GH pathway activation. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This compound is studied by endocrinology research programs, pharmacokinetics laboratories, and institutions investigating sustained-release peptide delivery strategies.

This product is supplied as a lyophilized powder and is intended for laboratory and research use only. Not for human consumption. Each vial contains 5mg of research-grade material.

Research Applications

  • Sustained GH secretion studies
  • Lean mass and fat metabolism
  • Bone health research
  • Sleep regulation through GH pathways

Specifications

Size
5mg
Purity
≥98% (HPLC)
Form
Lyophilized Powder
Molecular Formula
C152H252N44O42
Molecular Weight
3367.95 g/mol

Storage & Handling

  • Long-term storage: -20°C in a sealed, light-protected container
  • Short-term storage: 2-8°C (refrigerated) for up to 30 days
  • Reconstituted: Store at 2-8°C and use within 30 days
  • Avoid: Repeated freeze-thaw cycles, direct sunlight, and moisture exposure
  • Reconstitution: Use bacteriostatic water or sterile water for injection

Frequently Asked Questions

What is CJC-1295 (with DAC) and how does it work?
CJC-1295 with DAC is a modified GHRH analogue featuring a Drug Affinity Complex — a maleimide derivative of lysine that covalently binds to serum albumin after injection. This albumin binding extends the peptide's half-life from minutes to 6-8 days, enabling sustained stimulation of pituitary GH release through continuous GHRH receptor activation. This produces elevated GH and IGF-1 levels over an extended period in research models.
What research has been done on CJC-1295 (with DAC)?
Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single administration of CJC-1295 with DAC elevated GH levels for 6+ days and IGF-1 levels for 9-11 days in human subjects. Phase 2 studies showed dose-dependent increases in both GH and IGF-1 with good tolerability. Preclinical research has explored its effects on body composition, sleep architecture (through GH-mediated slow-wave sleep), and bone density.
How does CJC-1295 with DAC compare to Tesamorelin?
Both are GHRH analogues, but they differ significantly in pharmacokinetics. CJC-1295 with DAC provides sustained GH elevation over 6-8 days due to albumin binding, while tesamorelin has a shorter duration requiring daily administration. Tesamorelin has FDA approval for HIV lipodystrophy and more extensive clinical trial data. CJC-1295 with DAC is more commonly used in research studying prolonged GH exposure effects.
What is the recommended reconstitution protocol for CJC-1295 (with DAC)?
For this 5mg vial, reconstitute with 1mL of bacteriostatic water for a 5mg/mL solution. The DAC modification makes this peptide slightly more complex to dissolve — allow 3-5 minutes. Add water slowly along the vial wall. Do not shake, as the maleimide group can be sensitive to agitation. Store at 2-8°C and use within 30 days.
What purity testing is performed on CJC-1295 (with DAC)?
CJC-1295 with DAC undergoes HPLC analysis (minimum 98% purity) with specific attention to the integrity of the DAC (maleimide) modification. Mass spectrometry verifies the complete molecular weight including the DAC group. Additional tests include amino acid analysis, free maleimide content (to ensure proper conjugation), endotoxin testing, and residual solvent screening. A COA is provided.

Related Products

CJC-1295 + Ipamorelin 10mg
10mg In Stock

CJC-1295 + Ipamorelin

Synergistic GH secretagogue blend for body composition research.

$89.00
Ipamorelin 10mg
10mg In Stock

Ipamorelin

Highly selective synthetic pentapeptide GH secretagogue for research.

$79.00
CJC-1295 (without DAC) 10mg
10mg In Stock

CJC-1295 (without DAC)

Modified GHRH analogue for growth hormone release research.

$79.00

Research Use Only. This product is not intended for human consumption, therapeutic use, or diagnostic purposes. All peptides sold by Elyte Peptides are strictly for in-vitro research and laboratory use. By purchasing, you agree to use this product in compliance with all applicable laws and regulations.